ArticleFrontiers in nutrition2025
Stress hyperglycemia ratio and risk of incident myocardial infarction in the general population: a large-scale cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Stress hyperglycemia ratio in coronary artery disease: a systematic review and meta-analysis of severity and prognosis.Cardiovascular diabetology · 2026Pooled it
- Stress-hyperglycemia ratio, its longitudinal trajectories, and stress-metabolism synergy in predicting cardiometabolic multimorbidity: A nationwide prospective cohort study.The Journal of international medical research · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stress hyperglycemia ratio (SHR), which combines acute admission glucose with chronic glycemic indices, is a novel marker of stress hyperglycemia. Its association with acute myocardial infarction (AMI) risk in the general population remains unclear. Methods: This prospective cohort study used data from the UK Biobank and included 337,620 participants without known cardiovascular disease (CVD). SHR was calculated as admission glucose/[(28.7 × HbA1c%) - 46.7], with levels categorized into quintiles. The primary outcome was incident AMI, while ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) were evaluated as secondary outcomes. Cox proportional hazards models assessed the relationship between SHR and incident AMI risk. An accelerated failure time model was used to evaluate the effect of SHR on time to AMI onset, and dynamic changes in SHR were analyzed using a restricted cubic spline (RCS). Results: During a median follow-up of 164.8 months (IQR: 155.7-173.6), 10,598 AMI events, including 3,019 STEMI and 5,711 NSTEMI cases, were recorded. Compared with the fourth quintile, the first, second, and third quintiles had increased AMI risks by 19% (HR 1.19; 95% CI 1.12-1.27), 16% (HR 1.16; 95% CI 1.09-1.24), and 7% (HR 1.07; 95% CI 1.00-1.14), respectively, with no significant increase observed in the highest quintile. RCS analysis revealed a U-shaped relationship between SHR and incident AMI risk (P for non-linearity < 0.001), with the lowest risk at an SHR of 0.966. Conclusion: In the general population without known CVD, SHR exhibited a U-shaped association with incident AMI risk, with the lowest risk observed at an SHR of 0.966, particularly at levels below this threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.